IRIS
DE LAURENTIIS, MICHELINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.360
EU - Europa 2.039
AS - Asia 1.953
AF - Africa 47
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.411
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.277
SG - Singapore 899
IT - Italia 740
CN - Cina 450
HK - Hong Kong 445
NL - Olanda 257
DE - Germania 231
FI - Finlandia 188
IE - Irlanda 181
UA - Ucraina 154
VN - Vietnam 99
CA - Canada 75
GB - Regno Unito 75
RU - Federazione Russa 51
FR - Francia 48
SE - Svezia 48
CI - Costa d'Avorio 36
IN - India 34
AT - Austria 17
CZ - Repubblica Ceca 8
BR - Brasile 6
BE - Belgio 5
MX - Messico 5
TW - Taiwan 5
BG - Bulgaria 4
ES - Italia 4
IR - Iran 4
JO - Giordania 4
LT - Lituania 4
AL - Albania 3
BD - Bangladesh 3
BZ - Belize 3
CH - Svizzera 3
EG - Egitto 3
JP - Giappone 3
PL - Polonia 3
RO - Romania 3
ZA - Sudafrica 3
CO - Colombia 2
EU - Europa 2
HR - Croazia 2
KE - Kenya 2
LI - Liechtenstein 2
MA - Marocco 2
MD - Moldavia 2
SI - Slovenia 2
AM - Armenia 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
ID - Indonesia 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
NO - Norvegia 1
NP - Nepal 1
PK - Pakistan 1
RS - Serbia 1
SA - Arabia Saudita 1
TN - Tunisia 1
Totale 7.411
Salva come PNG Salva come JPEG
Città #
Singapore 742
Chandler 457
Hong Kong 441
Santa Clara 310
Millbury 270
Amsterdam 239
Jacksonville 160
Princeton 156
Naples 130
Ashburn 124
Nanjing 115
Beijing 98
Dong Ket 98
Napoli 92
Wilmington 88
Des Moines 77
Ottawa 65
Boston 64
Munich 64
Helsinki 48
Lawrence 48
Milan 44
Nanchang 41
Seattle 41
Dublin 29
Hebei 26
Rome 23
Tianjin 23
Shenyang 22
Jiaxing 21
Norwalk 21
Nuremberg 21
Pune 18
Boardman 16
Moscow 16
Falls Church 15
Houston 14
Salerno 13
London 12
Kunming 11
Frankfurt am Main 9
Kronberg 9
Shenzhen 9
Changsha 8
Fairfield 8
Giugliano In Campania 8
Toronto 8
Washington 8
Woodbridge 8
Cookstown 7
Formia 7
New York 7
Palermo 7
Pomigliano d'Arco 7
Bologna 6
Casoria 6
Indiana 6
Massa di Somma 6
Redwood City 6
Vienna 6
Afragola 5
Brno 5
Caivano 5
Dearborn 5
Fort Worth 5
Lanzhou 5
Mexico City 5
Sant'Agnello 5
Shanghai 5
Wuhan 5
Amman 4
Catanzaro 4
Changchun 4
Columbus 4
Dallas 4
Falkenstein 4
Harrow 4
Kortrijk 4
Leawood 4
Samara 4
Sofia 4
Somma Vesuviana 4
Springfield 4
Acton 3
Angri 3
Battipaglia 3
Belize City 3
Council Bluffs 3
Craiova 3
Edinburgh 3
Granada 3
Guangzhou 3
Johannesburg 3
Lappeenranta 3
Los Angeles 3
Montauro 3
Olomouc 3
Pavia 3
Pellezzano 3
Perugia 3
Totale 4.612
Salva come PNG Salva come JPEG
Nome #
Manuale di Oncologia Clinica 108
Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells 108
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 95
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 92
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 84
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 71
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 69
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 67
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 67
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 63
Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5 59
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 58
Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. 58
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 58
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 58
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 56
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 55
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 54
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 51
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 49
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 49
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 48
An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer 48
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial 47
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies 47
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 46
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 46
Virtual reality and music therapy as distraction interventions to alleviate anxiety and improve mood states in breast cancer patients during chemotherapy 46
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 45
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. 45
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 45
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 44
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 44
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer 44
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 44
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 44
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. 43
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 43
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype 43
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients 43
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 43
A predictive index of axillary nodal involvement in operable breast cancer. 42
Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. 42
A metanalysis of interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)”, 42
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial 42
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 41
Amyloid in bone marrow smears of patients affected by multiple myeloma. 41
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. 41
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial 41
Triple-Negative Breast Cancer comparison with Canine Mammary Tumors from light microscopy to molecular pathology 41
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. 40
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. 40
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 40
Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series 40
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 39
CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia 39
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 39
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. 38
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. 37
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA 37
Prognostic significance of multifocality in primary breast cancer. 37
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. 37
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 37
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 37
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 37
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients 37
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 36
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 36
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. 36
Inhibition of cardiomyocytes late INa with ranolazine to prevent anthracyclines cardiotoxicity in experimental models in vitro and in vivo 36
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab 36
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. 35
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 35
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 35
Treatment of triple negative brest cancer (TNBC): current options and future perspectives. 35
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial 35
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 35
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. 34
DNA-flow cytometry (ploidy and s-phase fraction) as prognostic factor in a retrospective series of 515 primary breast-cancer 34
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice 34
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer 34
A technique for using neural network analysis to perform survival analysis of censored data. 33
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study 33
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 33
Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease 33
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. 32
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 32
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. 32
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 32
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. 31
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. 31
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 31
A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results 31
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. 30
Survival Analysis by means of a novel Neural Network Model 30
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. 30
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. 30
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 30
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials 30
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial 30
Totale 4.431
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.329
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.329
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020289 0 0 0 0 0 0 9 16 13 81 79 91
2020/2021626 20 27 72 46 45 78 49 11 103 17 50 108
2021/20221.113 9 4 10 4 21 50 15 45 175 90 202 488
2022/20231.345 225 95 38 79 130 125 12 81 190 248 100 22
2023/20241.160 44 168 161 77 50 79 13 81 12 22 199 254
2024/20252.286 458 583 42 75 150 347 631 0 0 0 0 0
Totale 7.832